Bellevue Group’s AbbVie ABBV Stock Holding History

Bellevue Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$9K	–	202
2019 Q1	$9K	Buy	+200	New	+$16.4K	﹤0.01%	137

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bellevue Group's ABBV Position: Q2 2026 in Review

Bellevue Group reduced its AbbVie (ABBV) stake by 57% in Q2 2026, selling an estimated $11.4M and leaving 40,476 shares worth $10.2M. The position accounts for 0.21% of the portfolio, ranked #70.

Bellevue Group first reported a position in ABBV in Q1 2016 and has held it in 35 quarters since. The position peaked at $50.5M in Q1 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Bellevue Group held 40,476 shares of AbbVie worth $10.2M as of Q2 2026.
Bellevue Group sold 53,091 AbbVie shares in Q2 2026, an estimated $11.4M.
AbbVie made up 0.21% of Bellevue Group's portfolio in Q2 2026, its #70 holding.
Bellevue Group first reported a position in AbbVie in Q1 2016 and has held it in 35 quarters since.
Bellevue Group's AbbVie position peaked at $50.5M in Q1 2022.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.